-
Vioxx risk varies according to patient
What have we learned about the cardiovascular risk of Vioxx, with so much media attention lately? Health Canada set up a 13-member expert panel to review and critique the scientific evidence for the Cox-2 painkillers Vioxx, Celebrex and Bextra. The panel recommended in its July report that Merck could resubmit Vioxx for approval.